Pelage Pharmaceuticals Phase 3 Trials for PP405 Start in September 2026 9/15/2026
Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)
Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.
community If PP405 works it will be fkn impossible to buy it.
PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
community PP405 Hairloss Reversal and Hairline Restoration
PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.
community Average r/bald user complaining
Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.
community We already know how to permanently fix hair loss. The science is done. The only thing missing is the funding to run one experiment.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
Related Research
6 / 6 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research LB1045 Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo
PP405 may help hair growth by activating hair follicle stem cells.
research Hair Analysis as an Environmental Health Bioindicator: A Case-Study using Pelage of the California Ground Squirrel (Spermophilus beecheyi)
This study reported that in the California Ground Squirrel, certain elements bioaccumulate in hair, providing baseline data for environmental health assessments.
research Étude des contaminants transportés par les microplastiques dans le milieu marin Libanais
This study found that microplastics on the Lebanese Mediterranean coast transport various organic and inorganic pollutants, posing threats to marine organisms and potentially human health.
research Next generation human skin constructs as advanced tools for drug development
This review discusses the advancements and challenges in developing in vitro human skin models incorporating components like vasculature for drug testing and disease research, but reports no new clinical results.